4yy4 › Citations

A Subset of Human Bromodomains Recognizes Butyryllysine and Crotonyllysine Histone Peptide Modifications.

Flynn EM, Huang OW, Poy F, Oppikofer M, Bellon SF, Tang Y, Cochran AG
Structure 23 1801-1814 (2015)
Related entries: 4yy6, 4yyd, 4yyg, 4yyh, 4yyi, 4yyj, 4yyk, 4yym, 4yyn

Cited: 99 times
EuropePMC logo PMID: 26365797

Abstract

Bromodomains are epigenetic readers that are recruited to acetyllysine residues in histone tails. Recent studies have identified non-acetyl acyllysine modifications, raising the possibility that these might be read by bromodomains. Profiling the nearly complete human bromodomain family revealed that while most human bromodomains bind only the shorter acetyl and propionyl marks, the bromodomains of BRD9, CECR2, and the second bromodomain of TAF1 also recognize the longer butyryl mark. In addition, the TAF1 second bromodomain is capable of binding crotonyl marks. None of the human bromodomains tested binds succinyl marks. We characterized structurally and biochemically the binding to different acyl groups, identifying bromodomain residues and structural attributes that contribute to specificity. These studies demonstrate a surprising degree of plasticity in some human bromodomains but no single factor controlling specificity across the family. The identification of candidate butyryl- and crotonyllysine readers supports the idea that these marks could have specific physiological functions.

Articles - 4yy4 mentioned but not cited (1)

  1. Insights into the Ligand Binding to Bromodomain-Containing Protein 9 (BRD9): A Guide to the Selection of Potential Binders by Computational Methods. De Vita S, Chini MG, Bifulco G, Lauro G. Molecules 26 7192 (2021)


Reviews citing this publication (39)

  1. Metabolic regulation of gene expression through histone acylations. Sabari BR, Zhang D, Allis CD, Zhao Y. Nat Rev Mol Cell Biol 18 90-101 (2017)
  2. Functions of bromodomain-containing proteins and their roles in homeostasis and cancer. Fujisawa T, Filippakopoulos P. Nat Rev Mol Cell Biol 18 246-262 (2017)
  3. Lysine Acetylation Goes Global: From Epigenetics to Metabolism and Therapeutics. Ali I, Conrad RJ, Verdin E, Ott M. Chem Rev 118 1216-1252 (2018)
  4. Acetylation & Co: an expanding repertoire of histone acylations regulates chromatin and transcription. Barnes CE, English DM, Cowley SM. Essays Biochem 63 97-107 (2019)
  5. Insights into newly discovered marks and readers of epigenetic information. Andrews FH, Strahl BD, Kutateladze TG. Nat Chem Biol 12 662-668 (2016)
  6. Compartmentalised acyl-CoA metabolism and roles in chromatin regulation. Trefely S, Lovell CD, Snyder NW, Wellen KE. Mol Metab 38 100941 (2020)
  7. The many lives of KATs - detectors, integrators and modulators of the cellular environment. Sheikh BN, Akhtar A. Nat Rev Genet 20 7-23 (2019)
  8. Epigenomic regulation of oncogenesis by chromatin remodeling. Kumar R, Li DQ, Müller S, Knapp S. Oncogene 35 4423-4436 (2016)
  9. The Current State of NAD+ -Dependent Histone Deacetylases (Sirtuins) as Novel Therapeutic Targets. Schiedel M, Robaa D, Rumpf T, Sippl W, Jung M. Med Res Rev 38 147-200 (2018)
  10. Diverse Activities of Histone Acylations Connect Metabolism to Chromatin Function. Dutta A, Abmayr SM, Workman JL. Mol Cell 63 547-552 (2016)
  11. YEATS Domain-A Histone Acylation Reader in Health and Disease. Zhao D, Li Y, Xiong X, Chen Z, Li H. J Mol Biol 429 1994-2002 (2017)
  12. Histone acylations and chromatin dynamics: concepts, challenges, and links to metabolism. Nitsch S, Zorro Shahidian L, Schneider R. EMBO Rep 22 e52774 (2021)
  13. The Functions of BET Proteins in Gene Transcription of Biology and Diseases. Cheung KL, Kim C, Zhou MM. Front Mol Biosci 8 728777 (2021)
  14. Biological function and histone recognition of family IV bromodomain-containing proteins. Lloyd JT, Glass KC. J Cell Physiol 233 1877-1886 (2018)
  15. Reading the Combinatorial Histone Language. Su Z, Denu JM. ACS Chem Biol 11 564-574 (2016)
  16. Selectivity on-target of bromodomain chemical probes by structure-guided medicinal chemistry and chemical biology. Galdeano C, Ciulli A. Future Med Chem 8 1655-1680 (2016)
  17. Chromatin dynamics and histone modifications in intestinal microbiota-host crosstalk. Fellows R, Varga-Weisz P. Mol Metab 38 100925 (2020)
  18. Protein lysine crotonylation: past, present, perspective. Jiang G, Li C, Lu M, Lu K, Li H. Cell Death Dis 12 703 (2021)
  19. Chemical Protein Degradation Approach and its Application to Epigenetic Targets. Itoh Y. Chem Rec 18 1681-1700 (2018)
  20. The Regulation and Function of Histone Crotonylation. Ntorla A, Burgoyne JR. Front Cell Dev Biol 9 624914 (2021)
  21. Unwinding chromatin at the right places: how BAF is targeted to specific genomic locations during development. Ho PJ, Lloyd SM, Bao X. Development 146 dev178780 (2019)
  22. Functional Roles of Bromodomain Proteins in Cancer. Boyson SP, Gao C, Quinn K, Boyd J, Paculova H, Frietze S, Glass KC. Cancers (Basel) 13 3606 (2021)
  23. The Contribution of Histone Crotonylation to Tissue Health and Disease: Focus on Kidney Health. Martinez-Moreno JM, Fontecha-Barriuso M, Martín-Sánchez D, Sánchez-Niño MD, Ruiz-Ortega M, Sanz AB, Ortiz A. Front Pharmacol 11 393 (2020)
  24. Chemical probes targeting epigenetic proteins: Applications beyond oncology. Ackloo S, Brown PJ, Müller S. Epigenetics 12 378-400 (2017)
  25. Targeting BRD9 for Cancer Treatment: A New Strategy. Zhu X, Liao Y, Tang L. Onco Targets Ther 13 13191-13200 (2020)
  26. An Expanding Repertoire of Protein Acylations. Xu Y, Shi Z, Bao L. Mol Cell Proteomics 21 100193 (2022)
  27. Structural features and inhibitors of bromodomains. Meslamani J, Smith SG, Sanchez R, Zhou MM. Drug Discov Today Technol 19 3-15 (2016)
  28. Pathways of Non-enzymatic Lysine Acylation. Baldensperger T, Glomb MA. Front Cell Dev Biol 9 664553 (2021)
  29. Small Molecules Targeting the Specific Domains of Histone-Mark Readers in Cancer Therapy. Zhu H, Wei T, Cai Y, Jin J. Molecules 25 E578 (2020)
  30. Emerging roles of non-histone protein crotonylation in biomedicine. Hou JY, Zhou L, Li JL, Wang DP, Cao JM. Cell Biosci 11 101 (2021)
  31. Oncometabolites drive tumorigenesis by enhancing protein acylation: from chromosomal remodelling to nonhistone modification. Fu Y, Yu J, Li F, Ge S. J Exp Clin Cancer Res 41 144 (2022)
  32. Chemogenomics for drug discovery: clinical molecules from open access chemical probes. Quinlan RBA, Brennan PE. RSC Chem Biol 2 759-795 (2021)
  33. Chemical Biology Approaches to Identify and Profile Interactors of Chromatin Modifications. Nickel GA, Diehl KL. ACS Chem Biol 18 1014-1026 (2023)
  34. NUT Is a Driver of p300-Mediated Histone Hyperacetylation: From Spermatogenesis to Cancer. Rousseaux S, Reynoird N, Khochbin S. Cancers (Basel) 14 2234 (2022)
  35. Recent progress and structural analyses of domain-selective BET inhibitors. Divakaran A, Harki DA, Pomerantz WCK. Med Res Rev 43 972-1018 (2023)
  36. Beyond metabolic waste: lysine lactylation and its potential roles in cancer progression and cell fate determination. Wang JH, Mao L, Wang J, Zhang X, Wu M, Wen Q, Yu SC. Cell Oncol (Dordr) 46 465-480 (2023)
  37. Catching Nucleosome by Its Decorated Tails Determines Its Functional States. Sehrawat P, Shobhawat R, Kumar A. Front Genet 13 903923 (2022)
  38. Epigenetic meets metabolism: novel vulnerabilities to fight cancer. Scumaci D, Zheng Q. Cell Commun Signal 21 249 (2023)
  39. Functions and mechanisms of protein lysine butyrylation (Kbu): Therapeutic implications in human diseases. Xue Q, Yang Y, Li H, Li X, Zou L, Li T, Ma H, Qi H, Wang J, Yu T. Genes Dis 10 2479-2490 (2023)

Articles citing this publication (59)



Quick links